PAVmed Inc (PAVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PAVmed Inc (PAVM) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-896.00K) by net assets ($25.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PAVM stock market capitalisation for the company's overall valuation and market capitalisation.
PAVmed Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how PAVmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PAVmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PAVmed Inc ranked by their cash flow conversion efficiency. Explore PAVM cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MANTLE MINERALS
F:MXB0
|
N/A |
|
Mare Nostrum
PA:ALMAR
|
-0.054x |
|
IPB Petroleum Ltd
AU:IPB
|
0.000x |
|
CDT Environmental Technology Investment Holdings Limited ordinary shares
NASDAQ:CDTG
|
-0.023x |
|
Sparta Capital Ltd
V:SAY
|
-0.429x |
|
Techgen Metals Ltd
AU:TG1
|
-0.102x |
|
Social Housing REIT plc
LSE:SOHO
|
0.034x |
|
South HARZ Potash Ltd
AU:SHP
|
-0.877x |
Annual Cash Flow Conversion Efficiency for PAVmed Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of PAVmed Inc from 2014 to 2024. View latest PAVmed Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.03 Million | $-33.55 Million | 4.771x | +120.21% |
| 2023-12-31 | $-24.02 Million | $-52.04 Million | 2.167x | +133.37% |
| 2022-12-31 | $10.93 Million | $-70.98 Million | -6.492x | -1170.21% |
| 2021-12-31 | $79.42 Million | $-40.59 Million | -0.511x | -101.10% |
| 2020-12-31 | $-473.00K | $-21.91 Million | 46.330x | +1508.74% |
| 2019-12-31 | $-4.64 Million | $-13.36 Million | 2.880x | -18.85% |
| 2018-12-31 | $-2.48 Million | $-8.79 Million | 3.549x | +52.97% |
| 2017-12-31 | $-2.85 Million | $-6.61 Million | 2.320x | -83.38% |
| 2016-12-31 | $-319.07K | $-4.45 Million | 13.962x | +808.29% |
| 2015-12-31 | $633.92K | $-1.25 Million | -1.971x | -2499.63% |
| 2014-12-31 | $794.83K | $-60.27K | -0.076x | -- |
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more